Inhibitory effect of vasoactive intestinal polypeptide (VIP) on experimental liver metastasis by murine colon 26-L5 carcinoma cells

Oncology Research

Volumn 10, Issue 7, 1998, Pages 361-370

  Ogasawara, Masaru ^a   Murata, Jun ^a   Ayukawa, Koichi ^a   Saiki, Ikuo ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Colon carcinoma; Invasion; Metastasis; Motility; VIP

Indexed keywords

FIBRONECTIN; LAMININ; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL ADHESION; CELL CULTURE; CELL MOTION; COLON TUMOR; DOSE RESPONSE; DRUG EFFECT; LIVER TUMOR; METASTASIS; MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING; TIME;

ANIMALS; BLOTTING, SOUTHERN; CELL ADHESION; CELL MOVEMENT; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRONECTINS; LAMININ; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TUMOR CELLS, CULTURED; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0032248711     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Poste, G.; Fidler, I. J. The pathogenesis of cancer metastasis. Nature 283:139-146; 1980.
2. Liotta, L. A. Tumor invasion and metastasis - role of the extracellular matrix: Rhoads memorial award lecture. Cancer Res. 46:1-7; 1986.
3. Stracke, M. L.; Murata, J.; Aznavoorian, S.; Littoa, L. A. The role of the extracellular matrix in tumor cell matastasis. In Vivo 8: 49-58; 1994.
4. Ogasawara, M.; Murata, J.; Ayukawa, K.; Saiki, I. Differential effect of intestinal neuropeptides on invasion and migration of colon carcinoma cells in vitro. Cancer Lett. 116:111-116; 1997.
5. Said, S. I.; Mutt, V. Potent peripheral and splanchnic vasodilator peptide from normal gut. Nature 225: 863-864; 1970.
6. Said, S. I.; Mutt, V. Polypeptide with broad biological activity: Isolation from small intestine. Science 169:1217-1218; 1970.
7. Giachetti, A.; Said, S. I.; Reynolds, R. C.; Koniges, F. C. Vasoactive intestinal polypeptide in brain: Localization in and release from isolated nerve terminals. Proc. Natl. Acad. Sci. USA 74: 3424-3428; 1977.
8. Jessen, K. R.; Saffrey, M. J.; Noorden, S. V.; Bloom, S. R.; Polak, J. M.; Burnstock, G. Immunohistochemical studies of the enteric nervous system in tissue culture and in situ: Localization of vasoactive intestinal polypeptide (VIP), substance-P and enkephalin
9. immunoreactive nerves in the guinea-pig gut. Neuroscience 5: 1717-1735; 1980.
10. Larsson, L.-I.; Fahrenkrug, J.; Schaffalitzky de Muckadell, O.; Sundler, F.; Hakanson, R.; Rehfeld, J. F. Localization of vasoactive intestinal polypeptide (VIP) to central and peripheral neurons. Proc. Natl. Acad. Sci. USA 73:3197-3200; 1976.
11. Ekblad, E.; Ekman, R.; Hakanson, R.; Sundler, F. Projections of peptide-containing neurons in rat colon. Neuroscience 27:655-674; 1988.
12. Usdin, T. B.; Bonner, T. I.; Mezey, E. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 135:2662-2680; 1994.
13. Ishihara, T.; Shigemoto, R.; Mori, K.; Takahashi, K.; Nagata, S. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 8:811-819; 1992.
14. 2 receptor: Molecular characterization of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett. 334:3-8; 1993.
15. Sreedharan, S. P.; Patel, D. R.; Huang, J. X.; Goetzl, E. J. Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor. Biochem. Biophys. Res. Commun. 193:546-553; 1993.
16. Adamou, J. E.; Aiyar, N.; Horn, S..V.; Elshourbagy, N. A. Cloning and functional characterization of the human vasoactive intestinal peptide (VIP)-2 receptor. Biochem. Biophys. Res. Commun. 209:385-392; 1995.
17. Sreedharan, S. P.; Robichon, A.; Peterson, K. E.; Goetzl, E. J. Cloning and expression of the human vasoactive intestinal peptide receptor. Proc. Natl. Acad. Sci. USA 88:4986-4990; 1991.
18. Krejs, G. J.; Fordtran, J. S.; Bloom, S. R.; Fahrenkrug, J.; Schaffalitzky De Muckadell, O. B.; Fischer, J. E.; Humphrey, C. S.; Walsh, J. H.; Shulkes, A. A. Effect of VIP infusion on water and ion transport in the human jejunum. Gastroenterology 78:722-727; 1980.
19. Itoh, H.; Lederis, K. P.; Rorstad, O. P. Relaxation of isolated bovine coronary arteries by vasoactive intestinal peptide. Eur. J. Pharmacol. 18:199-205; 1990.
20. Ahren, B.; Alumets, J.; Ericsson, M.; Fahrenkrung, J.; Fahrenkrung, L.; Hakanson, R.; Hedner, P.; Loren, L; Melander, A.; Rerup, C.; Sundler, F. VIP occurs in intrathyroidal nerves and stimulates thyroid hormone secretion. Nature 287:343-345; 1980.
21. Johnston, J. A.; Taub, D. D.; Lloyd, A. R.; Conlon, K.; Oppenheim, J. J.; Kevlin, D. J. Human T lymphocyte chemotaxis and adhesion induced by vasoactive intestinal peptide. J. Immunol. 153:1762-1768; 1994.
22. Ishioka, C.; Yoshida, A.; Kimata, H.; Mikawa, H. Vasoactive intestinal peptide stimulates immunoglobulin production and growth of human B cells. Clin. Exp. Immunol. 87:504-508; 1992.
23. Gamet, L.; Murat, J.-C.; Remaury, A.; Remesy, C.; Valet, P.; Paris, H.; Denis-Pouxviel, C. Vasoactive intestinal peptide and forskolin regulate proliferation of the HT29 human colon adenocarcinoma cell line. J. Cell. Physiol. 150:501-509; 1992.
24. Zia, H.; Hida, T.; Jakowlew, S.; Birrer, M.; Gozes, Y.; Reubi, J. C.; Fridkin, M.; Gozes, I.; Moody, T. W. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. Cancer Res. 56:3486-3489; 1996.
25. Moody, T. W.; Zia, F.; Draoui, M.; Brenneman, D. E.; Fridkin, M.; Davidson, A.; Gozes, I. A. Vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth. Proc. Natl. Acad. Sci. USA 90:4345-1349; 1993.
26. Jiang, S.; Kopras, E.; McMichael, M.; Bell, R. H., Jr.; Ulrich, C. D., II. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells. Cancer Res. 57:1475-1480; 1997.
27. Pincus, D. W.; DiCicco-Bloom, E. M.; Black, I. B. Vasoactive intestinal peptide regulates mitosis, differentiation and survival of cultured sympathetic neuroblasts. Nature 343:564-566; 1990.
28. Hoosein, N. M.; Logothetis, C. J.; Chung, L. W. Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells. J. Urol. 149:1209-1213; 1993.
29. Ohnishi, Y.; Sakamoto, T.; Fujii, H.; Kimura, F.; Murata, J.; Tazawa, K.; Fujimaki, M.; Sato, Y.; Kondo, M.; Une, Y.; Uchino, J.; Saiki, I. Characterization of a liver metastatic variant of murine colon 26 carcinoma cells. Tumor Biol. 18:113-122; 1997.
30. Saiki, I.; Murata, J.; Watanabe, K.; Fujii, H.; Abe, F.; Azuma, I. Inhibition of tumor cell invasion by Ubenimex (Bestatin) in vitro. Jpn. J. Cancer Res. 80:873-878; 1989.
31. Metwail, A.; Elliott, D.; Blum, A. M.; Li, J.; Sandor, M.; Weinstock, J. V. Tcell vasoactive intestinal peptide receptor subtype expression differs between granulomas and spleen of schistosome-infected mice. J. Immunol. 157:265-270; 1996.
32. Slezak, S. E.; Horan, P. K. Fluorescent in vivo tracking of hematopoietic cells. Part I. Technical considerations. Blood 74:2172-2177; 1989.
33. Ashraf, S.; Crowe, R.; Loizidou, M.C.; Turmaine, M.; Taylor, I.; Burnstock, G. The absence of autonomic perivascular nerves in human colorectal liver metastases. Br. J. Cancer 73:349-359; 1996.
34. Frixen, U. H.; Behrens, J.; Sachs, M.; Eberle, G.; Warda, A.; Lochner, D.; Birchmeier, W. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human cacinoma cells. J. Cell Biol. 113:173-185; 1991.
35. 17] VIP. Am. J. Physiol. 250:G553-G557; 1986.
36. Lampugnani, M. G.; Giorgi, M.; Gaboli, M.; Dejana, E.; Marchisio, P. C. Endothelial cell motility, integrin receptor clustering, and microfilament organization are inhibited by agents that increase intracellular cAMP. Lab. Invest. 63:521-531; 1990.
37. Martinez, C.; Delgado, M.; Gomariz, R. P.; Ganea, D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide-38 inhibit IL-10 production in murine T lymphocytes. J. Immunol. 156:4128-4136; 1996.
38. Luis, J.; Muller, J.-M.; Abadie, B.; Martin, J.-M.; Marvaldi, J.; Pichon, J. Cycle of the vasoactive intestinal peptide and its binding site in a human adenocarcinoma cell line (HT 29). Eur. J. Biochem. 156:631-636; 1986.
39. Boissard, C.; Hejblum, G.; Marie, J.-C.; Gespach, C.; Rosselin, G. C. R. Desensitization toVIP by down regulation of its peptide receptors in transformed HT-29 cells of human colonic epithelium in culture. C. R. Hebd. Seances Acad. Sci. 299:795-798; 1984.
40. Mitchell, B. S.; Schumacher, U.; Stauber, V. V.; Kaiserling, E. Are breast tumours innervated? Immunohistological investigations using antibodies against the neuronal marker protein gene product 9.5 (PGP 9.5) in benign and malignant breast lesions. Eur. J. Cancer 30A:1100-1103; 1994.